Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week Study
Antiviral Therapy2011Vol. 17(2), pp. 355–364
Citations Over TimeTop 10% of 2011 papers
Josep M. Llibre, María J. Buzón, Marta Massanella, Anna Esteve‐Codina, Viktor Dahl, María C. Puertas, Peré Domingo, Josep M. Gatell, Maria Larrouse, Mar Gutiérrez, Sarah Palmer, Mario Stevenson, Julià Blanco, Javier Martínez‐Picado, Bonaventura Clotet
Abstract
Intensification of HAART with raltegravir during 48 weeks was safe and associated with a significant decrease in CD8(+) T-cell activation, and a transient increase of episomal HIV-1 DNA. However, raltegravir did not significantly contribute to changes in CD4(+) T-cell counts, ultrasensitive VL, and total and integrated HIV-1 DNA. These findings suggest that raltegravir impacts residual HIV-1 replication and support new strategies to impair HIV-1 persistence. ClinicalTrials.gov identifier: NCT00554398.
Related Papers
- → Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy(2010)73 cited
- → Single Mutations in HIV Integrase Confer High-Level Resistance to Raltegravir in Primary Human Macrophages(2011)27 cited
- → Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)(2010)19 cited
- → Role of raltegravir in the management of HIV-1 infection(2011)10 cited
- → Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection(2010)1 cited